A newly surfaced internal memo from the U.S. Food and Drug Administration (FDA) has sparked debate after chief medical and scientific officer Vinay Prasad stated that COVID-19 vaccinations may have contributed to at least 10 cases of fatal heart inflammation in children. According to the memo, seen by Reuters, Prasad said the staff’s preliminary review suggested “likely, probable, or possible” vaccine attribution in these deaths. He described the findings as significant, noting it would mark the first time the FDA acknowledged potential fatal vaccine-related cases in American children.
The analysis reviewed 96 child deaths reported between 2021 and 2024. While it did not identify the children’s underlying medical conditions or the vaccine manufacturers involved, Prasad said that the early assessment found no fewer than 10 cases potentially linked to COVID-19 vaccination. He added that examining deaths involving children aged 7 to 16 was especially difficult.
Health Secretary Robert F. Kennedy Jr. has recently shifted U.S. vaccine policy, restricting access to COVID-19 vaccines to individuals 65 and older and those with certain conditions. Kennedy, long known for his skepticism toward vaccines, has criticized past vaccine policies promoted under both the Trump and Biden administrations.
Experts have urged caution in interpreting the memo. The FDA’s assessment has not been peer-reviewed or published in a medical journal, and critics—including UC Law San Francisco professor Dorit Reiss—argue that policy changes should not stem from unpublished investigations. Reiss also noted Prasad is not a vaccine specialist.
Despite concerns raised in the memo, FDA Commissioner Marty Makary emphasized that COVID-19 vaccines were highly effective for older adults, especially when matched to circulating variants. Recent research also supports the benefits of updated vaccines in reducing severe illness and hospitalization among high-risk groups.
CDC data shows 1,071 U.S. children aged 5 to 18 died from COVID-19 between early 2020 and mid-2023. Prasad argued that it remains unclear how vaccination influenced those outcomes, stating that voluntary reporting and unknown prevention metrics complicate comparisons.
The memo is expected to fuel continued discussion ahead of an upcoming CDC vaccine committee meeting.


Kim Jong Un Oversees Missile Test Amid Rising Korean Peninsula Tensions
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
U.S. Prioritizes Economic Pressure With Venezuelan Oil Quarantine as Sanctions Intensify
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Italy Fines Apple €98.6 Million Over App Store Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Trump Administration Proposes Sweeping Limits on Gender-Affirming Care for Children
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Anutin Charnvirakul Named Bhumjaithai PM Candidate Ahead of Thailand’s February Election
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
China’s One-Child Policy Legacy Resurfaces After Death of Former Population Chief 



